Cargando…

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study

At week 48 in the phase IIIb DAWNING study, the integrase strand transfer inhibitor (INSTI) dolutegravir plus 2 nucleoside reverse transcriptase inhibitors demonstrated superiority to ritonavir-boosted lopinavir in achieving virologic suppression in adults with HIV-1 who failed first-line therapy. H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Underwood, Mark, Horton, Joe, Nangle, Keith, Hopking, Judy, Smith, Kimberly, Aboud, Michael, Wynne, Brian, Sievers, Jörg, Stewart, Eugene L., Wang, Ruolan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Antiviral Agents
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765460/ https://www.ncbi.nlm.nih.gov/pubmed/34694877 http://dx.doi.org/10.1128/AAC.01643-21

Ejemplares similares

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study
por: Vavro, Cindy, et al.
Publicado: (2022)

Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase
por: Bonnard, Damien, et al.
Publicado: (2023)

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
por: Tsiang, Manuel, et al.
Publicado: (2016)

Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance
por: Demarest, James, et al.
Publicado: (2018)

Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes
por: White, Kirsten L., et al.
Publicado: (2021)

Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine
por: Jeffrey, Jerry L., et al.
Publicado: (2022)

Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs
por: Boyer, Paul L., et al.
Publicado: (2019)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
por: Himmel, Daniel M., et al.
Publicado: (2020)

Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection
por: Mehta, Rashmi, et al.
Publicado: (2018)

Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine
por: Walimbwa, Stephen I., et al.
Publicado: (2019)

Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques
por: McMillan, JoEllyn, et al.
Publicado: (2017)

Repurposing Nucleoside Analogs for Human Coronaviruses
por: Zandi, Keivan, et al.
Publicado: (2020)

The Small-Compound Inhibitor K22 Displays Broad Antiviral Activity against Different Members of the Family Flaviviridae and Offers Potential as a Panviral Inhibitor
por: García-Nicolás, Obdulio, et al.
Publicado: (2018)

Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor
por: Wang, Li, et al.
Publicado: (2021)

Antiviral Properties of HIV-1 Capsid Inhibitor GSK878
por: Wang, Chunfu, et al.
Publicado: (2023)

Characterization of Influenza B Virus Variants with Reduced Neuraminidase Inhibitor Susceptibility
por: Farrukee, R., et al.
Publicado: (2018)

Discovery of M Protease Inhibitors Encoded by SARS-CoV-2
por: Hung, Hui-Chen, et al.
Publicado: (2020)

Screening of Natural Extracts for Inhibitors against Japanese Encephalitis Virus Infection
por: Guo, Jiao, et al.
Publicado: (2020)

Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus
por: Feng, Joy Y., et al.
Publicado: (2016)

Original Chemical Series of Pyrimidine Biosynthesis Inhibitors That Boost the Antiviral Interferon Response
por: Lucas-Hourani, Marianne, et al.
Publicado: (2017)

Src Family Kinase Inhibitors Block Translation of Alphavirus Subgenomic mRNAs
por: Broeckel, Rebecca, et al.
Publicado: (2019)

Protamine Sulfate Is a Potent Inhibitor of Human Papillomavirus Infection In Vitro and In Vivo
por: Young, Jesse M., et al.
Publicado: (2022)

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
por: Smith, Steven J., et al.
Publicado: (2014)

Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025)
por: Softic, Laurent, et al.
Publicado: (2020)

GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile
por: Dicker, Ira, et al.
Publicado: (2022)

7‐Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir
por: Ziegler, Robert E., et al.
Publicado: (2018)

Biochemical activity of RAGs is impeded by Dolutegravir, an HIV integrase inhibitor
por: Nilavar, Namrata M., et al.
Publicado: (2020)

Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731
por: Huang, Qi, et al.
Publicado: (2020)

Structural Insights into the Mechanisms of Action of Functionally Distinct Classes of Chikungunya Virus Nonstructural Protein 1 Inhibitors
por: Kovacikova, Kristina, et al.
Publicado: (2021)

Novel Nonnucleoside Inhibitors of Zika Virus Polymerase Identified through the Screening of an Open Library of Antikinetoplastid Compounds
por: Sáez-Álvarez, Yanira, et al.
Publicado: (2021)

Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2
por: Kuo, Chih-Jung, et al.
Publicado: (2021)

The use of integrase inhibitors in treatment-experienced patients
por: Gatell, Jose M
Publicado: (2009)

Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor
por: Coates, Matthew, et al.
Publicado: (2017)

Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages
por: Sake, Svenja M., et al.
Publicado: (2022)

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir
por: Ng, Teresa I., et al.
Publicado: (2017)

Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C
por: Ulferts, Rachel, et al.
Publicado: (2016)

Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro
por: Gammeltoft, Karen A., et al.
Publicado: (2021)

TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells
por: Bam, Rujuta A., et al.
Publicado: (2016)

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir
por: Ng, Teresa I., et al.
Publicado: (2017)

Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity
por: Nevers, Quentin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4oit2fpvq8g1533khtp3dhdhcc